Antiviral therapy for chronic hepatitis B in China

Xin Zheng · Junzhong Wang · Dongliang Yang

Received: 10 March 2014 / Accepted: 15 October 2014 / Published online: 25 December 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract The vaccination program against hepatitis B virus (HBV) has greatly reduced the incidence of HBV infection. However, almost one-fourth of the HBV infected patients worldwide are still located in China. The healthcare burden from chronic HBV infection is a big challenge for the Chinese government and clinicians. Antiviral therapy plays a central role in controlling chronic HBV infection and preventing the disease progression. However, due to the specific economic and medical system issues, the first-line antiviral agents recommended by the AASLD and EASL have not been widely used for Chinese patients. In this review, we will discuss some key issues in the area of antiviral treatment for chronic hepatitis B in China.

Keywords Chronic hepatitis B · Antiviral therapy · Drug resistance · China

Introduction

There are about 350 million people worldwide suffering from chronic hepatitis B virus (HBV) infection. China is one of the countries with a high prevalence of HBV infection [1]. The HBV vaccination program for all newborns was implemented by the Chinese government in 1992, which increased the yearly national HBV vaccine inoculation rate. Based on this achievement, the prevalence of HBV surface antigen (HBsAg) carrier in the general population (1–59 years old) of China was decreased from 9.75 % in 1992 to 7.18 % in 2006 [1]. Despite the reduction in the incidence of HBV infection, there are still about 93 million people chronically infected with HBV and an estimated 20 million cases of symptomatic chronic hepatitis B in China now. Therefore, the healthcare burden from chronic HBV infection is still a big challenge for China.

Patients with chronic HBV infection may develop liver fibrosis, cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC) and eventually die from liver failure and other complications [2]. Numerous studies have shown that active HBV replication leads to liver injury and disease progression [3]. As pointed out by the “Guidelines for prevention and treatment of chronic hepatitis B” from the American Association for the Study of liver disease (AASLD), European Association for the Study of the Liver (EASL), Asia Pacific Association for the Study of the Liver (APASL), and Chinese Association for the Study of liver disease (CASLD), the ultimate long-term goal of treatment is to prevent hepatic decompensation, reduce progression to cirrhosis and/or HCC, and prolong survival [4]. The short-term goal is to permanently suppress HBV replication. Therefore, antiviral therapy plays a central role in controlling chronic HBV infection and preventing the disease progression. Due to economic and medical system issues, the antiviral treatment in China has its own unique characteristics [5]. In this review, we will discuss some key issues in the area of antiviral treatment for chronic hepatitis B in China.

Patients who need antiviral therapy

Patients with positive serum HBsAg for more than 6 months or patients with positive HBsAg and chronic liver
disease proven by biopsy can be diagnosed with chronic HBV infection. Based on the information from the guidelines for management of chronic hepatitis B virus infection published by CASLD in 2010, the indications for antiviral therapy are as follows:

General indications: (1) For HBeAg positive patients with serum HBV DNA $\geq 10^5$ copies/mL (equivalent to 20,000 IU/mL) and for HBeAg negative patients with HBV DNA $\geq 10^4$ copies/mL (equivalent to 2,000 IU/mL); (2) alanine transaminase (ALT) $\geq 2$ upper limit of normal (ULN), but for patients treated with interferon-α (IFN-α), ALT should be $\leq 10$ ULN and the total bilirubin should be $<2$ ULN; and (3) ALT $< 2$ ULN, but the liver biopsy shows a histological activity index (Knodell HAI) $\geq 4$, or degree of necroinflammation $\geq G2$, or degree of fibrosis $\geq S2$.

For patients with persistently positive HBV DNA who do not show the criteria mentioned above, the antiviral therapy should be applied if they are in the following conditions:

1. Patients older than 40 years and ALT $> ULN$.
2. For patients older than 40 years and ALT is sustained normal, a liver biopsy is recommended. If the Knodell HAI is $\geq 4$, or the degree of necroinflammation $\geq G2$, or the degree of fibrosis $\geq S2$, then antiviral therapy should be applied.
3. If disease progression is evident, for example, spleen enlargement, liver biopsy is recommended, and antiviral therapy should be applied if necessary [1].

As to the standards for determining the patients who need antiviral therapy, CASLD has very similar rules as AASLD, EASL, or APASL. All these associations recommend that the patients need to be evaluated based on the state of persistent HBsAg, HBeAg, the level of HBV DNA, and the degree of liver inflammation and fibrosis, and clinicians may decide whether the patients are appropriate for antiviral therapy. Histology of the liver biopsy provides direct evidence for grading the inflammation and staging the fibrosis in the liver; however, liver biopsy is hard to perform in most hospitals because of the patients’ refraction.

ALT is routinely tested as a biochemical marker to reflect the degree of the liver inflammation, it is one of the important markers for identifying whether the patient in an immune activation stage or not. The ULN for ALT is defined as 40 U/L in China based on the results of a national wide survey in the 1950s [6, 7]. However, increasing evidence from China shows that this reference value cannot dependably reflect the degree of the liver inflammation. For chronic hepatitis B patients with persistently normal ALT, the liver biopsy results showed that 34.4 % of them had fibrosis with degree $\geq S2$ or fibrosis degree $\geq S1$ and inflammation degree $\geq G2$ [8]. Another study reported that in patients with ALT $< 0.5$ ULN, the proportion with significant liver inflammation and fibrosis was 16.6 %, whereas in patients with ALT between 0.5 and 1 ULN, the proportion increased to 40 % [9]. For patients with ALT between 1 ULN and 2 ULN, the proportion of fibrosis could be up to 61.8 % [8]. These data indicate that the ULN of ALT may need to be revised for China.

A large sample survey in Italy showed the ULN of ALT should be 30 U/L for healthy men and 19 U/L for healthy women [10]. The guidelines of AASLD in 2009 recommended to use these values to evaluate the liver inflammation status of the patients [11]. A study in Korea showed that the ULN of ALT for Koreans was 33 U/L for the healthy men and 25 U/L for healthy women [12], and these values had been applied in the guidelines for Korea in 2012 [13]. A large sample survey for ULN of ALT, including 28,642 healthy men and 24,413 healthy women was performed in China in 2011 and showed the ULN of ALT was 35 U/L for men and 23 U/L for women in Chinese Han population [14]. Based on these new findings, CASLD should adjust the ULN of ALT reference value in the next version of the guidelines. Otherwise, the patients with mildly elevated ALT (ALT between 1 ULN and 2 ULN) or persistently normal ALT may not receive the opportunity of antiviral therapy.

Drugs available for antiviral therapy in China

Two kinds of antiviral agents have been approved for the therapy of chronic hepatitis B: IFN-α and nucleot(s)ide analogs. The first includes conventional IFN-α and Peg-IFN-α, and the second includes lamivudine (LAM), adefovir dipivoxil (ADV), telbivudine (LdT), entecavir (ETV), and tenofovir (TFV). All these medicines are now available in China. The randomized clinical trials confirmed that Peg-IFN-α treatment could obtain a higher HBeAg seroconversion rate in a limited period of treatment; ETV and TFV have a potent antiviral effect, low incidence of drug resistance, and good safety [11, 15–19]. These drugs are listed as the first-line antiviral drugs for chronic hepatitis B treatment by AASLD and EASL. The conventional IFN-α, LdT, ADV, and LAM are the second-line antiviral drugs [11, 20]. In China, compared with the average yearly incomes of the general population, the Peg-IFN-α and ETV produced by foreign or Sino-foreign joint venture pharmaceutical companies are very expensive and are only covered by a small proportion of medicare payments, or not covered at all. Most of Chinese patients with chronic hepatitis B cannot afford Peg-IFN-α or ETV, and consequently these drugs are rarely used for the initial antiviral treatment. The clinicians have to choose from the second-line drugs with affordable prices for the patients, especially in rural areas. By using
With the development of local pharmaceutical companies, the generic drugs of conventional IFN-α, LAM, ADV, and ETV have been successfully produced and approved for the treatment of chronic hepatitis B in China. The application of domestic produced Peg-IFN-α in chronic hepatitis B is still in clinical trial. The multicenter, large sample clinical studies show that there are no significant differences in antiviral efficacy, bioavailability, and safety between the domestic IFN-α/nucleot(s)ide analogs and the original drugs [21–23]. The price of domestic generic drugs is only 50–70 % of the original drugs. This provides more choices for the clinician in addition to reducing the economic pressure on the patients.

Traditional Chinese medicines (TCM) have been used for treating chronic hepatitis B for a long time. Over 90 % of chronic hepatitis B patients received the TCM therapy [24]. Preclinical and clinical trials, which were performed in China, indicated that some traditional Chinese medicine preparations, like phyllanthus urinaria, decoction of small bupleurum (a medicinal root found natively in East Asia), matrine (an alkaloid found in plants from the Sophora genus with anticancer activity), or rhubarb, had a potential effect on inhibiting HBV replication, regulating the hosts’ immune function, and improving liver function [25, 26]. A short-term clinical follow-up study found that matrine treatment could result in a similar curative effect to interferon in HBeAg seroconversion and HBV DNA reduction [27]. The small bupleurum decoction and phyllanthus urinaria preparations are reported to have a similar therapeutic effect as conventional IFN [26, 28]. Although it seems that TCM can be used as alternative medicine for antiviral treatment, the antiviral effect needs to be evaluated in well-designed and randomized clinical trials. In addition, the composition of TCM is very complex, and it is difficult to explain the mechanism from the standpoint of modern medicine. This limits the application of TCM in the treatment of chronic hepatitis B [25, 29].

The drug resistance and rescue strategies

Due to the low cost, the second-line nucleot(s)ide analogs (LAM, LdT, and ADV) are widely used in China. When the second-line NAs are chosen for long-term therapy regimens, drug resistance may occur and cause virologic breakthrough, hepatitis flare, and even death. Therefore, rescue strategies need to be taken once the resistant strains of HBV are detected. For the LAM-resistant strain, the therapy can switch to monotherapy with either Adefovir or Entecavir, add-on ADV to LAM or use a combination treatment of ADV and ETV. The experience from China is that ETV + ADV is superior to LAM + ADV, and LAM + ADV is better than monotherapy [30, 31]. However, due to the risk of frequent resistance development against ADV with LAM-resistant strains, further research is needed to assess long-term cost-effectiveness of ETV combination treatment to LAM-resistant disease. For the ADV-resistant strains, adding LAM, or LdT, or ETV to ADV is recommended [1]. Current research shows that both LdT + ADV combination therapy and ETV monotherapy leads to significant decreases in serum HBV DNA in the patients with resistance to ADV, and LdT + ADV combination therapy exhibits a significantly higher rate of HBeAg seroconversion than ETV monotherapy [32]. For the patients with resistance to LdT or ETV, adding ADV is recommended, but it’s antiviral efficacy and safety are not established [1]. A small sample survey showed that LdT + ADV combination therapy led to significant decreases in serum HBV DNA levels, normalization of ALT, and increased the rate of HBeAg seroconversion in patients with resistance to LdT [33].

Response guided therapy

The serum HBV DNA levels, serum ALT levels, HBV genotype, HBeAg status, and other factors in patients with initial antiviral treatment are important factors for predicting the response to antiviral therapy which has been called baseline guided therapy (BGT). In recent years, the response of patients to treatment during antiviral treatment as the guidance (response guided therapy, RGT) has become the focus of attention. A multicenter study on optimization of telbivudine (LdT) treatment led by Hou in China is based on the idea of RGT. Chronic hepatitis B patients were evaluated after 24 weeks of LdT monotherapy. If the serum level of HBV DNA was ≥300 copies/mL, patients were switched to LdT plus ADV combination therapy. Otherwise, patients would maintain LdT monotherapy. After 105 weeks of treatment, the rates of HBV DNA < 300 copies/mL in the LdT plus ADV group and the LdT group were not significantly different (76.7 vs. 61.2 %). However, the rates of viral mutations and drug resistance were significantly different between these two groups (6.0 vs. 30.4 %, 2.7 vs. 25.8 %) [34].

Combination therapy

Combination antiviral therapy strategy has been used for rescue therapy and RGT. It is uncertain whether it should
be used for initial treatment. Some studies indicated that initial combination antiviral treatment can improve efficacy and reduce the rates of viral mutations in HBeAg positive CHB patients with high viral load (≥10⁸ IU/mL) and in decompensated cirrhosis patients who need long-term NAs antiviral therapy [35, 36]. The combination of IFN-α and NA or two NAs are the mainstream strategy for combination treatment. Although there are some reports from China showed that combination treatment was significantly superior to monotherapy (see Table 1) [37]. However, the CASLD does not recommend the initial LAM-ADV combination therapy for CHB patients.

TCM are also candidates for combination therapy. The combination of matrine and nucleot(s)ide analogs, such as LAM, has synergistic effect and can achieve even better therapeutic effects for inhibiting HBV replication. They can restore liver function quickly and reduce the incidence of virus bounce after withdrawal of the nucleot(s)ide analogs [25, 27]. But it need further study to confirm.

Prospective

It is clear that many chronic HBV patients have benefited from antiviral treatment. The incidence of liver fibrosis, cirrhosis, hepatic decompensation, and HCC has been reduced. However, the clinicians have new challenges to face. In the US and European countries, primary non-response and suboptimal response is rare in patients who received TDF and ETV treatment, but may occur due to pharmaceutical response of the host to the drugs. In China, poor adherence of patients to treatment, relative high costs of the first-line antiviral drugs and resistance development may be the key factors that cause the non-response, suboptimal response, and even treatment failure. Since 2008, several large cohort studies supported by the government have been carried out on the optimizing strategy for the treatment of chronic hepatitis B in China. This may serve as one of the important ways to solve this problem and to benefit most of the patients. In addition, recent studies show that the agonist of Toll-like receptor 7 and HBsAg/HBsAb immune complex can induce prolonged suppression of hepatitis B virus in chronically infected individuals by stimulating the innate and acquired immune response. Therefore, the immune modulation therapy may be a new strategy for antiviral treatment on chronic hepatitis B.

Acknowledgments This work was supported by Grants from National Major Science and Technology Project for Infectious Diseases of China (2008ZX10002011, 2012ZX10004503), the International Science and Technology Cooperation Program of China (2011DFA31030), and the Deutsche Forschungsgemeinschaft (Transregio TRR60).

| Groups | Virologic response % | HBeAg clearance % | HBeAg seroconversion % | ALT normalization % | Drug resistance % | Time (weeks) | Number of patients | References |
|--------|----------------------|------------------|------------------------|---------------------|------------------|-------------|-------------------|------------|
| LAM + ADV | 100 | 51 | 46.9 | 10 | 0 | 96 | 50 | He et al. [38] |
| LAM | 66 | 21 | 49 | 10 | 0 | 96 | 50 | Li et al. [39] |
| ADV | 90.6 | 33 | 64 | 21.9 | 5 | 90 | 52 | Zeng et al. [40] |
| Peg-IFN-α-2a + ETV | 100 | 30 | 66.8 | 30 | 5 | 90 | 32 | Ma et al. [41] |
| Peg-IFN-α-2a | 90 | 15 | 80 | 15 | 5 | 90 | 40 | Cao et al. [37] |
| Peg-IFN-α-2a + ADV | 48.6 | 12.5 | 48.6 | 12.5 | 5 | 90 | 40 | |
| Peg-IFN-α-2a + LAM | 100 | 75 | 100 | 75 | 5 | 90 | 40 | |

Means that no data were reported.
Conflict of interest  The authors have no conflict of interests to declare to this review.

Ethical standard  Based on the regulations of the Ministry of Health, all clinical research project conducted in China, must be approved by the medical ethical committee of the corresponding institution.

Open Access  This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association (2011) The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi 19:13–24
2. Lok AS (2013) Hepatitis: long-term therapy of chronic hepatitis B reverses cirrhosis. Nat Rev Gastroenterol Hepatol 10:199–200
3. Liaw YF (2013) Reduction of cirrhosis and hepatocellular carcinoma with antiviral therapy in chronic hepatitis B. Hepatology 58:1856
4. Liaw YF (2013) Impact of therapy on the outcome of chronic hepatitis B. Liver Int 33(Suppl 1):111–115
5. Sun J, Hou JL (2010) Management of chronic hepatitis B: experience from China. J Viral Hepat 17(Suppl 1):10–17
6. Karmen A, Wroblewski F, Ladue JS (1955) Transaminase activity in human blood. J Clin Invest 34:126–131
7. Kaplan MM (2002) Alanine aminotransferase levels: what’s normal? Ann Intern Med 137:49–51
8. Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Hai-Jun H (2013) Comparison of histologic characteristics of chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS ONE 8:e80585
9. Gui HL, Wang H, Yang YH, Wu YW, Zhou HJ, Guo SM, Lin LY et al (2010) Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase. J Viral Hepat 17(Suppl 1):44–50
10. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L et al (2002) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137:1–10
11. Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50:661–662
12. Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, Lim YS, Chung YH et al (2010) Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 51:1577–1583
13. Korean Association for the Study of the Liver (2012) KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 18:109–162
14. Zheng MH, Shi KQ, Fan YC, Liu WY, Lin XF, Li LF, Chen YP (2012) Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population. PLoS ONE 7:e43736
15. Janssen HL., van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C et al (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBsAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123–129
16. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM et al (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351:1206–1217
17. Chang TT, Gish RG, de Man RA, Gadano A, Sollano J, Chao YC, Lok AS et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001–1010
18. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH et al (2007) Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133:1437–1444
19. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G et al (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359:2442–2455
20. European Association For The Study Of The Liver (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57:167–185
21. Dong PL, Wang DM, Zhang XM, Zhang B, Ding HG, Min J, Chen XY (2009) Efficacy and durability of generic adefovir dipivoxil in patients with HBeAg positive chronic hepatitis. Zhonghua Shi Yan He Lin Chuan Bing Du Xue Za Zhi 23:473–475
22. Zhao H, Zhang YX, Chen XY, Wang L, Tang XP, Si CW (2007) A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B. Zhonghua Nei Ke Za Zhi 46:294–297
23. Wang H, Wang QH, Wang HF, Jia JD, Xie W, Qin XQ (2004) A clinical study of the efficacy and safety of secretory human interferon alpha-2a treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 12:589–592
24. Wong VW, Law MY, Hui AL, Li CY, Soo MT, Leung HY et al (2005) A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. Complement Ther Med 13:175–182
25. Chen Y, Zhu J (2013) Anti-HBV effect of individual traditional Chinese herbal medicine in vitro and in vivo: an analytic review. J Viral Hepat 20:445–452
26. He J, Zhou D, Tong G, Xing Y, Chen Y, Zhang X, Zhan B et al (2013) Efficacy and safety of a Chinese herbal formula (invigorating kidney and strengthening spleen) in chronic hepatitis B virus carrier: results from a multicenter, randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med 2013:961926
27. Ma ZZ, Li Q, Wang JB, Zhao YL, Zhong YW, Bai YF, Wang RL et al (2013) Combining oxymatrine or matrine with lamivudine increased its antireplication effect against the hepatitis B virus in vitro. Evid Based Complement Alternat Med 2013:186573
28. Guo Z, Yu S, Guan Y, Li YY, Lu Y, Zhang H, Su SB (2012) Molecular mechanisms of same TCM syndrome for different diseases and different TCM syndrome for same disease in chronic hepatitis B and liver cirrhosis. Evid Based Complement Alternat Med 2012:120350
29. Wang R, Kong J, Wang D, Lien LL, Lien EJ (2007) A survey of Chinese herbal ingredients with liver protection activities. Chin Med 2:5
30. Xu XH, Li GL, Qin Y, Li Q, He FQ, Li JY, Pan QR et al (2013) Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice. Virol J 10:162
31. Hu M, Zhang G, Diao S, Lin M, Wu J, Sun L, She H et al (2012) Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy. Intern Med 51:1509–1515
32. Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H (2013) Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. J Viral Hepat 20(Suppl 1):40–45
33. Zhang Y, Lian JQ, Li Y, Wang JP, Huang CX, Bai XF (2013) Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. Eur J Gastroenterol Hepatol 25:814–819
34. Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R et al (2013) 104-week efficacy and safety of telbivudine based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology 59:1283–1292
35. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M (2007) Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445–1451
36. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, Brosart CL et al (2008) Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 48:728–735
37. Cao Z, Zhang Y, Ma L, Sun G, He Z, Liu Y, Jin Y et al (2010) Treatment of HBeAg-positive CHB infection with peginterferon alfa-2a [40KD] (PEGASYS) plus lamivudine or adefovir for 96 weeks results in high rates of HBsAg clearance/seroconversion. Hepatology 52(suppl 1):507A
38. He Z, Wang J, Liu K, Huang H, Du Y, Lin Z, Cai M et al (2012) Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B. Clin Res Hepatol Gastroenterol 36:592–597
39. Li Y, Chen ZT, Wu JC, Gan JH, Chen JJ, Zhao WF, Luo EP (2012) Efficacy and safety of telbivudine and adefovir dipivoxil for the treatment of chronic hepatitis B patients with high level hepatitis B virus load and hepatitis B e antigen-positivity. Zhonghua Gan Zang Bing Za Zhi 20:859–860
40. Zeng W, Yuan J, Liu YX, Zhang Y, Li SX, Yao SM, Lin YM et al (2013) Efficacy of Peg-interferon alpha-2a combined with entecavir on HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 27:115–118
41. Ma W, Zhou B, Ao F, Zhou D, Hu Y, He Q, Dai W et al (2009) Higher sustained post-treatment virologic response following peginterferon alfa-2a ± adefovir compared with adefovir monotherapy in HBeAg-positive patients. Hepatology 50(Suppl 5):494A